With BYETTA, there is no increased risk of hypoglycemia when used with metformin and/or a thiazolidinedione (TZD)
For
your patients
<< BYETTA InfoSite
Home
Safety and tolerability:
No
increased risk of hypoglycemia in combination with metformin and/or a TZD.
Sulfonylureas
increase the risk of hypoglycemia.[2]
When BYETTA is used with a sulfonylurea, there is an increased risk of
hypoglycemia. To reduce this risk, reduction in the dose of the sulfonylurea
may be considered.
The
most common adverse event in the 30-week clinical trials was nausea (44%
vs 18% for placebo).
3%
dropout rate due to nausea over 30 weeks in clinical trials (vs <1% for
placebo).
Most
patients who experienced nausea experienced it upon initiation of therapy.
With BYETTA®, there is no increased risk of hypoglycemia when used with metformin and/or a TZD
Safety and tolerability:
Details about hypoglycemia and nausea
Hypoglycemia
No
increased risk of hypoglycemia in combination with metformin and/or a TZD. Sulfonylureas
increase the risk of hypoglycemia.[2]
When BYETTA is used with a sulfonylurea, there is an increased risk of
hypoglycemia. To reduce this risk, reduction in the dose of the sulfonylurea
may be considered.Nausea
The
most common adverse event in the 30-week clinical trials was nausea (44%
vs 18% for placebo).— Almost
all of these events were characterized as mild to moderate (94% vs 95%
for placebo), and decreased over time in most patients.[1]
— In a study vs insulin glargine, the rates were similar to the 30-week trials.[1]
— In a study vs insulin glargine, the rates were similar to the 30-week trials.[1]
3%
dropout rate due to nausea over 30 weeks in clinical trials (vs <1% for
placebo). Most
patients who experienced nausea experienced it upon initiation of therapy.